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Abstract 
Background: Bongardia chrysogonum is widely used in Turkey for treating urinary tract infections and prostate 
hypertrophy, and it also has potent hypoglycemic effects and aids glucose homeostasis. Because of the inflammatory 
conditions in diabetes mellitus (DM), the prostate tissue of men with diabetes is particularly susceptible to developing 
hypoplasia, and DM produces characteristic pathological changes in prostate tissue. Here, we examined the effects of 
B. chrysogonum on the prostate tissue of rats with streptozotocin (STZ)-induced diabetes.
Results: The glucose levels were statistically significantly higher in the diabetic rats than in healthy controls 
(P < 0.001). Further, they were significantly lower in the healthy and diabetic rats administered B. chrysogonum than in 
the untreated diabetic rats (P < 0.001 and 0.05, respectively). The total cholesterol levels were significantly lower in the 
healthy rats administered B. chrysogonum than the healthy controls (P < 0.05) and diabetic rats (P < 0.01). They were 
also significantly lower in the diabetic rats administered B. chrysogonum than those that were left untreated (P < 0.05). 
The testosterone levels were significantly lower in the untreated diabetic rats than in the controls (untreated ones and 
those administered B. chrysogonum) and diabetic rats administered the herb (P < 0.001, 0.05 and 0.01, respectively). 
The oxidative stress index was significantly higher in the untreated diabetic rats than the healthy controls (P < 0.05). 
It was also significantly lower in the healthy and diabetic groups treated with B. chrysogonum than the untreated 
diabetic rats (P < 0.05). Histological examination showed no changes in the prostate tissue of the non-diabetic rats. 
In the diabetic group, the glandular lumens were filled with cellular debris and leucocytic infiltrate, and the glandular 
epithelium was degenerated and thickened. In the diabetic group treated with B. chrysogonum, the epithelium was 
better preserved and less debris was seen in the glandular lumen.
Conclusion: To our knowledge, this is the first study to histologically prove the effects of B. chrysogonum on prostate 
tissue in diabetes. Our findings may be useful in developing B. chrysogonum into a therapeutic agent against diabetes 
and benign prostate hyperplasia.
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Background
Benign prostatic hyperplasia (BPH) is character-
ized by narrowing of the urethral opening as a result 
of the growth of prostate tissue around the urethra 
(COMMİTTEE 2003). Histological BPH is observed 
in 8 % of men between 31 and 40 years of age, the inci-
dence increases markedly with age, and reaches about 
90 % in the 9th decade of life (Rosen et  al. 2003, 2005), 
and this condition greatly hampers quality of life. 
Although most literature implicates non-controllable 
factors like age, hormonal status, and genetics in BPH, 
newer publications link it to metabolic factors such as 
high blood glucose and blood lipid levels, and the field is 
rapidly advancing (Parsons 2007). Thus, new targets for 
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prevention and treatment of BPH may be revealed in the 
near future.
As with BPH, the incidence of diabetes mellitus (DM) 
increases with age, and developed communities need to 
allocate a large share of healthcare expenses toward these 
diseases. Between 3.5 and 4.2 million men in the United 
States have both BPH and DM. When treating either of 
these diseases, however, the possible presence of other 
pathologies must be kept in mind, as the population most 
commonly affected by them is the elderly (Klein et  al. 
2005).
Bongardia chrysogonum is a tuberous plant used in the 
treatment of certain diseases in south-east Anatolia. Its 
use particularly in the treatment of urinary tract infec-
tions, prostate hypertrophy, hypercholesterolemia, epi-
lepsy, and cancer has increased its national demand, and 
it is marketed throughout Turkey (Arslan et al. 2005). B. 
chrysogonum also reportedly has potent hypoglycemic 
effects and is useful for glucose homeostasis, in addi-
tion to multiple anti-inflammatory effects exerted via 
saponins (Arslan et al. 2005). Saponins are fat- and water-
soluble glycosides that combine with glycan or aglycan 
components of B. chrysogonum. They inhibit the emulsi-
fication of fat molecules and bile acids via reducing their 
surface tension and detergent effects in the gastrointes-
tinal tract. Another well-defined anti-hypercholester-
olemic mechanism of saponins is the ability to change the 
quantity and dimension of cholesterol micelles, which 
reduces their absorption by intestinal mucosa cells (Rah-
man et al. 2000; Rao and Kendall 1986; Sidhu and Oaken-
full 1986; Whitehead et al. 1981), with consequent effects 
on metabolism.
In the present study, we examined the effects of B. chry-
sogonum on prostate tissue in a rat model with streptozo-
tocin (STZ)-induced diabetes in terms of the histological 
and biochemical aspects.
Methods
The ethics committee of Mustafa Kemal University 
approved the animal use protocol for this study, which 
is in compliance with the Declaration of Helsinki (ID: 
40595970/126). Male Wistar albino rats were used (250–
300  g) in this study. They were housed in a 12  h light 
and dark environment at room temperature. During the 
experiment, the rats were provided normal mouse pellets 
and water. Throughout the experiment, the animal condi-
tions were maintained according to international ethical 
guidelines for laboratory animals.
Animal protocol
Forty adult male Wistar albino rats were divided into 
four groups [control (C), diabetes group (D), B. chrysog-
onum group (B), and diabetes +  B. chrysogonum group 
(DB)] of 10 rats each. During the test period, the rats in 
all groups were given normal mouse pellets and water. At 
the beginning of the experiment, the blood sugar levels in 
all animals were measured using a glucometer. The rats in 
groups D and DB were administered 60 mg/kg STZ intra-
venously (prepared by dissolving STZ in citrate buffer). 
After 72 h, the urine of rats from groups D and DB was 
examined for glucose levels using strip analyzers. Rats 
with blood glucose concentrations ≥300 mg/dL (and for 
the urine samples, the color of the strip changed from 
yellow to green) were considered diabetic (Gulturk et al. 
2010).
Preparation of B. chrysogonum infusion
Bongardia chrysogonum obtained from a local herbal-
ist was crushed, and an infusion was prepared by pass-
ing 100 mL of boiled water through 3 g of this material. 
A fresh infusion was prepared each week before the test 
phase (Arslan et al. 2005).
Administration of B. chrysogonum
The rats in groups B and DB were administered 0.2 mL of 
the infusion obtained as mentioned above by oral gavage 
once every day for 5 weeks (Arslan et al. 2005). The rats 
in groups C and D were similarly administered 0.2 mL of 
water. At the end of the 5-week experiment, all rats were 
anesthetized using ketamine (90  mg/kg) and xylazine 
(3 mg/kg).
Hematological evaluation
Cardiac blood samples were collected, and the serum 
levels of glucose, total cholesterol (TC), high-density 
lipoprotein (HDL), low-density lipoprotein (LDL), and tri-
glycerides (TG) were measured using spectrophotometry.
Measurement of total antioxidant status
Serum total antioxidant status (TAS) levels were meas-
ured using the new automated method developed by Erel 
(2004). This assay has excellent precision (<3 %). In this 
method, the most powerful hydroxyl radicals are gener-
ated first. Reagent 1 containing ferrous ion solution is 
mixed with reagent 2, which includes hydrogen peroxide, 
n the assay. The brown-colored dianisidine radical cation 
is a strong radical produced by hydroxyl radicals. Non-
potent radical reactions initiated by the hydroxyl radi-
cals produced because of antioxidative effect of working 
examples were also measured. The results are expressed 
in mmol Trolox equivalents/L.
Measurement of total oxidant status
Serum total oxidative status (TOS) levels were also meas-
ured using the method of Erel (2005). In this method, 
oxidants present in the samples oxidize the ferrous 
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ion-o-dianisidine complex to ferric ions. The oxidation 
reaction is enhanced by abundant glycerol molecules in 
the reaction medium. The ferric ions form a colored com-
plex with xylenol orange in an acidic medium. The color 
intensity, which can be measured spectrophotometri-
cally, is related to the total amount of oxidant molecules 
in the sample. The assay was calibrated using hydrogen 
peroxide. The results are expressed in terms of micro-
moles of hydrogen peroxide equivalents per liter (μmol 
H2O2 equivalents/L).
Oxidative stress index
The percentage of the TOS to TAS ratio was used as the 
oxidative stress index (OSI) value [OSI  =  TOS (μmol 
H2O2 equivalents/L)/TAS (mmol Trolox equivalents/L)] 
(Dokuyucu et al. 2014).
Histopathological assessment
Renal and prostate samples were fixed in 10  % neutral 
buffered formalin for light microscopic examination. 
After the tissues were dehydrated in a graded alcohol 
series and embedded in paraffin, 5-μm-thick trans-
verse sections were prepared from the tissue blocks 
and stained with hematoxylin–eosin and reticulin for 
histologic evaluation. Sections were examined for char-
acteristic changes and photographed using an Olympus 
DP20 camera attached to an Olympus CX41 photomi-
croscope (American Diabetes Association 1998; McVary 
2006a, b).
Statistical analysis
Statistical analysis was performed using GraphPad soft-
ware, version 5.0 (GraphPad Inc., La Jolla, CA, USA). 
Normally distributed continuous variables were tested 
using one-way ANOVA and the post hoc Student’s t 
test. P values less than 0.05 were considered statistically 
significant.
Results
Glucose, TC, TG, HDL, LDL, and testosterone levels
The glucose levels were significantly higher in group 
D than in group C (P  <  0.001). Further, they were sig-
nificantly lower in groups B and DB than in group D 
(P < 0.001 and 0.05, respectively) (Table 1). No significant 
differences were found in the TC, TG, LDL, or HDL lev-
els between groups D and C. TC levels were significantly 
lower in group B than groups C and D (P < 0.05 and 0.01, 
respectively). They were also significantly lower in group 
DB than group D (P  <  0.05). The LDL levels were sig-
nificantly lower in group DB than in group D (P < 0.05) 
(Table 1). Lastly, the testosterone levels were significantly 
lower in group D than groups C, B, and DB (P < 0.001, 
0.05 and 0.01, respectively) (Table 1; Fig. 1). 
TAS, TOS, and OSI results
The TAS levels were significantly higher in group B than 
group C (P < 0.05), while the TOS levels were significantly 
higher in group D than groups C and DB (P < 0.05). The 
OSI levels were significantly higher in group D than 
group C (P < 0.05). They were also significantly lower in 
groups B and DB than group D (P < 0.05) (Table 1; Fig. 2).
Histopathological staining
Microscopic examination showed that the prostate tissue 
was normal in groups C (Fig. 3a) and B (Fig. 3b). In group 
D, the glandular lumens were filled with cellular debris 
and leucocytic infiltrate (Fig.  3c). The glandular epithe-
lium was also degenerated or thickened in some regions. 
Administration of B. chrysogonum improved the general 
tissue structure and the epithelium was better preserved 
and less debris was seen in the glandular lumen in group 
DB than in group D (Table 2; Fig. 3d).
Discussion
Inflammation is a generalized histopathologic finding of 
BPH (Fibbi et  al. 2010; Schauer and Rowley 2011) and 
is associated with a higher risk of lower urinary tract 
symptoms (LUTS) (Kramer and Marberger 2006) and 
acute urinary retention in aging men (Nickel et al. 2008). 
Recent studies have shown an increased risk of BPH in 
patients proven to have prostate inflammation on biopsy 
examination (Crawford et  al. 2006). In prostate tis-
sue developing hyperplasia, inflammation can induce 
proliferation events and nuclear deterioration through 
cytokines and oxidative stress (Naber and Weidner 2000). 
The aggressive release of oxygen radicals from mac-
rophages and neutrophils during acute or chronic inflam-
mation may lead to compensatory cellular proliferation, 
which further exacerbates oxidative stress, and in such 
conditions, hyperplastic proliferation may occur in the 
prostate tissue (Vital et al. 2015). Tanik et al. (2014) used 
inflammatory parameters like the neutrophil-to-lympho-
cyte ratio to predict BPH progression and LUTS severity 
and found a positive correlation between the neutrophil 
count and prostate hyperplasia.
High-fat diets (HFD) have also been implicated in 
oxidative stress and inflammation in the prostate gland 
(Shankar et al. 2012) as they increase the levels of acute-
phase inflammatory markers (Kriketos et  al. 2004) via 
cytokines released from neutrophils and macrophages 
in adipose tissue (Shankar et  al. 2015). Using a HFD-
induced metabolic syndrome animal model with hyper-
glycemia, dyslipidemia, and hypogonadism, Vignozzi 
et  al. (2012) linked metabolic syndrome to prostate 
inflammation, and found that it was correctible with 
testosterone replacement. Like HFD, DM has also been 
linked to chronic inflammatory conditions, and it has 
Page 4 of 7Dokuyucu et al. SpringerPlus  (2016) 5:1322 
been implicated in increasing cytokine levels, mostly in 
the adipose tissue (Gibb and Strachan 2014). Further, 
DM-related androgen deficiency has been observed in a 
third of the population with type 2 diabetes, although the 
underlying mechanism remains unclear (Cheung et  al. 
2015; Morton 2005). The prostate volume has been found 
to be especially high in male patients diagnosed with type 
2 diabetes (Kasturi et  al. 2006), and in the NHANES-3 
cohort study, Rohrman et al. observed a higher incidence 
of BPH in men with diabetes than in those without dia-
betes (American Diabetes Association 1998). Our results 
confirmed the effects of DM on prostate tissue shown 
in previous literature. A continuous supply of androgen 
Table 1 Laboratory data and levels of oxidative status in groups (mean ± SE)





e p < 0.05 vs. diabetes
f p < 0.01 vs. control
Control Diabetes (D) Bongardia (B) D + B
Glucose (mg/dL) 234.1 ± 16.72 584.4 ± 71.6a 195.4 ± 39.36b 307.6 ± 51.8c
T. cholesterol (mg/dL) 61.91 ± 7.63 61.52 ± 3.79 42.95 ± 3.04c,d 45.77 ± 5.00e
Triglycerids (mg/dL) 59.97 ± 11.00 56.42 ± 6.01 49.11 ± 5.68 52.68 ± 7.04
HDL (mg/dL) 16.01 ± 1.84 15.74 ± 1.46 10.72 ± 1.66 13.55 ± 1.15
LDL (mg/dL) 30.94 ± 4.31 34.43 ± 3.48 25.68 ± 4.11 22.88 ± 2.45e
TAS (mmol/L) 0.50 ± 0.03 0.66 ± 0.03 0.79 ± 0.08d 0.61 ± 0.05
TOS (mmol/L) 7.63 ± 1.11 13.79 ± 1.21d 9.44 ± 1.02 7.97 ± 1.85e
OSI (=TOS/TAS) 10.47 ± 1.18 19.15 ± 1.97d 12.00 ± 1.76e 12.94 ± 0.90e
Testosterone (mg/dL) 2.78 ± 0.48 0.36 ± 0.05a 1.76 ± 0.27e 0.94 ± 0.14f,c
Fig. 1 Comparison of the testosterone levels in groups
Fig. 2 Comparison of the oxidative stress index in groups
Table 2 The histopathology scores of  prostate tissues 
(mean ± SE)
a p < 0.0001
b p < 0.01, vs. control
c p < 0.0001
d p < 0.01, vs. diabetes
Control Diabetes (D) Bongardia (B) D + B
Leucocytic 
infiltrate




0.10 ± 0.10 2.50 ± 0.16a 0.20 ± 0.13c 1.12 ± 0.13b,d
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is crucial for the growth and normal functioning of the 
prostate gland, and when this supply stops or decreases, 
prostate disease may develop (Yadav and Heemers 2012).
Rahman et  al. (2000) conducted a detailed chemical 
examination of B. chrysogonum and examined the effects 
of saponins extracted from these tubers. Saponins are 
fat- and water-soluble glycosides with glycan or aglycan 
structures. In the intestine, saponins form micelles with 
bile acids, vitamins, fat acids, and diglycerides. Several 
studies have shown that because of a reduction in sur-
face tension and detergent effects in the gastrointestinal 
tract, saponins reduce the emulsification of fat molecules 
and bile acids (Rao and Kendall 1986; Sidhu and Oaken-
full 1986; Whitehead et al. 1981). Further, Bingham et al. 
(1978) showed that although saponins decreased the 
serum cholesterol and liver lipid concentrations, the liver 
cholesterol and serum HDL levels remain unchanged. 
The findings of our study agree with those of previous 
studies, as we clearly observed the anti-cholesterolemic 
and anti-lipidemic effects of B. chrysogonum in the blood 
and liver, respectively. Further, the testosterone levels 
in group D of the present study were significantly lower 
than those in group DB. These findings indicate that the 
hypogonadal status induced by DM was ameliorated by 
administration of B. chrysogonum. Additionally, correc-
tion of the deficiency in testosterone levels, which exac-
erbates prostate inflammation and tissue remodeling, 
may prevent or at least decelerate the course of BPH.
Arslan et al. (2005) and Assaf et al. (2013) studied the 
effects (Fig. 3) of B. chrysogonum on various tissues under 
certain conditions. However, to our knowledge, ours 
is the first study to histologically examine its effects on 
prostate tissues in DM.
Histologically at the cellular level, BPH is character-
ized by basal cell hyperplasia, increased stromal mass, 
enhanced extracellular matrix deposition, reduced elastic 
tissue, increased infiltration of leucocytes around ducts, 
and acinar hypertrophy (Bostwick et al. 1992).
The accumulation of inflammation throughout the 
prostatic tissue aggravates the process of prostatic 
Fig. 3 Comparison of the histopathologic parameters in groups. a Control group; b diabet group; c bongardia group; d diabet+bongardia group
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hyperplasia by enhancing the production of prostatic 
growth factors. Furthermore, the altered secretion of 
luminal cells and clogging of the ducts with debris and 
corpora amylacea may lead to prostatic calcification, 
which is a significant modification of the hyperplastic 
prostate. Our findings showed that the conditions of the 
prostate tissue were better in rats with diabetes who were 
treated with B. chrysogonum than in those that were not 
treated with this herb: as mentioned in the “Results” sec-
tion, the epithelium was better preserved and less debris 
was seen in the glandular lumen in group DB than in 
group D. Further, the TOS levels were significantly higher 
in group D than group DB, while the OSI levels were sig-
nificantly lower.
Chronic conditions such as DM and hypercholester-
olemia require lifelong treatment, and patient compliance 
may be better with alternative herbal treatment options 
in the case of such conditions. As indicated by our find-
ings, the well-known plant B. chrysogonum seems to have 
positive effects on glucose and lipid metabolism. Further, 
it seems to prevent the pathological changes that occur in 
the prostate tissue in DM. Thus, this herb may be a useful 
treatment option for patients with DM and BPH. Further 
molecular studies are needed to confirm the effects of B. 
chrysogonum on the prostate tissue and to develop this herb 
into an effective therapeutic agent against DM and BPH.
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